Bellicum Pharmaceuticals, Inc. is developing novel therapies that can be precisely controlled after delivery, for enhanced efficacy and ultimate safety. BPX-101 is an autologous vaccine in clinical development for patients with prostate cancer, and CaspaCIDe™ DLI is in clinical development for patients undergoing hematopoietic stem cell transplantation.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 03/01/12 | Series B | 20M | Unknown |
People
Thomas Farrell (CEO)
Kevin Slawin (Co-founder, President, CMO)
David Spencer (Co-founder, CSO)
View more details about the people at Bellicum Pharmaceuticals
News
Bellicum's prostate-cancer vaccine: Dendritic cells served with a genetic twist
October 12, 2007 9:52 pm
For a few brief months earlier this year, Dendreon‘s Provenge looked like it might become the first cancer vaccine approved… Continue reading ⟩
Life sciences briefing: Wednesday, Oct. 10, 2007
October 10, 2007 3:21 pm
Featured companies: 20/20 GeneSystems, Bellicum Pharmaceuticals, Cumbre Pharmaceuticals, Dara BioSciences, Enterprise Partners Venture Capital, Fermentas, International, Iasis Medical, New Leaf… Continue reading ⟩